Over 10 Million Merchants Join Five Fortune Card Campaign on Alipay Platform to Further Engage With Consumers Ahead of CNY
Over 10 million brands and merchants in China joined Alipay’s signature annual Five Fortune Card Collection campaign for the 2023 Chinese New Year, ramping up digital efforts to attract and engage mobile-savvy consumers, as Chinese consumers gear up for the most important festival of the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230121005044/en/
A user trying to collect a fortune card by scanning the Chinese character “fu” with AR scan feature in Alipay app (Photo: Business Wire)
This year’s campaign, from January 10, 2023 to January 21, attracted more than 30,000 blue chip and emerging international and domestic brands and over 10 million small and micro business participants seeking to enhance their interaction with Chinese consumers in anticipation of the Spring Festival. This represented a nearly 30 times increase in the number of brands that participated in the campaign last year.
“As an open platform, Alipay is committed to opening up products and technologies to facilitate merchants’ digital transformation. We have also introduced Five Fortune Card IP-related resources to our partners,” said Yongming He, General Manager of the Alipay Ecosystem Development Business Unit and Vice President of Ant Group. “We are glad to see a growing number of brands and merchants participating in the Alipay Five Fortune Card Collection campaign to enhance engagement with users and improve operational efficiency by leveraging digital tools, including mini program and livestreaming, on the Alipay platform.”
Initially launched in 2015, Alipay's Five Fortune Card Collection campaign is an annual event before the Chinese New Year. Users collect digital fortune cards by using the Alipay app's AR scan feature and participating in merchant campaigns, among various ways to win a fortune card. These cards represent good wishes and can be converted into monetary rewards.
This year, for the first time, users can receive a limited-edition digital collectible featuring Chinese intangible cultural heritage, including shadow puppetry, paper-cut and copper sculpture, after successfully obtaining five fortune cards in the campaign.
Users can win a fortune card when they scan the red envelope QR code each time at the outlets of the 10 million participating merchants. They may also obtain cards by logging into Alipay mini programs or by watching livestreams of more than 30,000 participating brands on Alipay. Through these livestreams, brands distributed fortune cards to participants, introduced their products and services, and gave out preferential benefits to build connections with mobile-savvy Chinese consumers.
Merchants and brands have seen significant digital engagement through their participation in the Alipay campaign, with millions of views from livestreaming. On January 11, No. 1 Job Club, a job search service provider, saw 20 million visits to their livestreaming on Alipay platform. On the same day, Yunchongbao, a pet service provider, witnessed 50 million visits to their Alipay livestream. And on January 15, the NBA attracted over 12 million visits to their Alipay livestream which was moderated by several local basketball influencers. These numbers demonstrate the success of the campaign in attracting digital participation from merchants and brands, as reflected in the large livestream audience engagement on the Alipay platform.
Pop-Mart, a culture and entertainment company that is best known for art and collectible toys who introduced the idea of "blind box”, attracted three million visits to their Alipay mini-program six days into the campaign, with its transaction volume through the Alipay platform increasing 300% compared with that of last month.
About Alipay
In the evolving digital era, Alipay has transformed from a trusted payment tool to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operations on the Alipay platform, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than one billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230121005044/en/
Contact information
Media Enquiry
Bell Wang
yixing.wl@antgroup.com
+86 138 1038 5201
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at Upcoming Investor Conferences28.10.2025 12:01:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:00 pm GMT/11:00 am EST Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through
Allianz Reports Safety Gains From Automated Mobility and Urges EU-Wide “Driving License” for Autonomous Vehicles28.10.2025 11:05:00 EET | Press release
The promise of autonomous mobility is not just a technological leap – it represents a transformation in safety, comfort, and accessibility that is already underway with Level 3 vehicles on European roads and Level 4 systems operating in real-world test fields. At the 13th Allianz Motor Day in 2025, hosted by the Allianz Center for Technology (AZT), Allianz unveiled significant safety gains from autonomous vehicles and calls for EU-wide testing standards to ensure their safe integration into European roads, including questions about vehicle safety, liability, the use of in-vehicle data from autonomous vehicles (AVs), and more inclusive mobility. The company already insures test fields in several countries, including Germany, Norway, and Singapore. AZT research and proprietary claims analysis indicate a significant decline in motor liability claims frequency driven by advanced driver assistance systems (ADAS) now available in select models. While these systems already demonstrate impress
Ares Management and Slate Asset Management to Acquire Polish Real Estate Portfolio Valued at Over €300 Million From Trei Real Estate28.10.2025 10:15:00 EET | Press release
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, and Slate Asset Management (“Slate”), a global investor and manager focused on essential real estate and infrastructure, today announced that a joint venture between Ares Real Estate funds (“Ares Real Estate”) and Slate has agreed to acquire a portfolio of 36 properties in Poland (the “Portfolio”) from Trei Real Estate, an internationally active developer and asset manager. The Portfolio is valued at over €300 million. The Portfolio comprises 36 recently developed and fully occupied convenience-led retail parks strategically located across major Polish metropolitan areas near large catchment populations. The assets are inflation-protected through CPI-linked lease agreements underpinned by tenants with strong covenants. Most of the Portfolio’s income is derived from large regional retailers and essential goods providers, including grocers and pharmacies. “This transaction underlines our c
SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia28.10.2025 10:00:00 EET | Press release
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity. The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development. My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green certification is the program’s highest designation, reserved for laboratories that demonstrate exceptional, independently verif
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 08:00:00 EET | Press release
Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru site marks a defining moment in Kemwell’s growth journey,” said Anurag Bagaria, Chairman and CEO, Kemwell Biopharma. “It reflects our team’s ste
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom